Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 11;22(1):692.
doi: 10.1186/s13063-021-05665-z.

Open-label randomized controlled trial of ultra-low tidal ventilation without extracorporeal circulation in patients with COVID-19 pneumonia and moderate to severe ARDS: study protocol for the VT4COVID trial

Jean-Christophe Richard  1   2   3 , Hodane Yonis  4 , Laurent Bitker  5   4   6 , Sylvain Roche  5   7   8 , Florent Wallet  9   10 , Claire Dupuis  11 , Hassan Serrier  12 , Laurent Argaud  13 , Guillaume Thiery  14 , Bertrand Delannoy  15 , Christian Pommier  16 , Paul Abraham  17 , Michel Muller  18 , Frederic Aubrun  19 , Florian Sigaud  20 , Guillaume Rigault  20   21 , Emilie Joffredo  9 , Mehdi Mezidi  5   4 , Nicolas Terzi  20   21   22 , Muriel Rabilloud  5   7   8
Affiliations

Open-label randomized controlled trial of ultra-low tidal ventilation without extracorporeal circulation in patients with COVID-19 pneumonia and moderate to severe ARDS: study protocol for the VT4COVID trial

Jean-Christophe Richard et al. Trials. .

Abstract

Background: Acute respiratory distress syndrome (ARDS) is a severe complication of COVID-19 pneumonia, with a mortality rate amounting to 34-50% in moderate and severe ARDS, and is associated with prolonged duration of invasive mechanical ventilation. Such as in non-COVID ARDS, harmful mechanical ventilation settings might be associated with worse outcomes. Reducing the tidal volume down to 4 mL kg-1 of predicted body weight (PBW) to provide ultra-low tidal volume ventilation (ULTV) is an appealing technique to minimize ventilator-inducted lung injury. Furthermore, in the context of a worldwide pandemic, it does not require any additional material and consumables and may be applied in low- to middle-income countries. We hypothesized that ULTV without extracorporeal circulation is a credible option to reduce COVID-19-related ARDS mortality and duration of mechanical ventilation.

Methods: The VT4COVID study is a randomized, multi-centric prospective open-labeled, controlled superiority trial. Adult patients admitted in the intensive care unit with COVID-19-related mild to severe ARDS defined by a PaO2/FiO2 ratio ≤ 150 mmHg under invasive mechanical ventilation for less than 48 h, and consent to participate to the study will be eligible. Patients will be randomized into two balanced parallels groups, at a 1:1 ratio. The control group will be ventilated with protective ventilation settings (tidal volume 6 mL kg-1 PBW), and the intervention group will be ventilated with ULTV (tidal volume 4 mL kg-1 PBW). The primary outcome is a composite score based on 90-day all-cause mortality as a prioritized criterion and the number of ventilator-free days at day 60 after inclusion. The randomization list will be stratified by site of recruitment and generated using random blocks of sizes 4 and 6. Data will be analyzed using intention-to-treat principles.

Discussion: The purpose of this manuscript is to provide primary publication of study protocol to prevent selective reporting of outcomes, data-driven analysis, and to increase transparency. Enrollment of patients in the study is ongoing.

Trial registration: ClinicalTrials.gov NCT04349618 . Registered on April 16, 2020.

Keywords: Acute respiratory distress syndrome; COVID-19; Mechanical ventilation; SARS-CoV-2; Tidal volume; Ultra-low tidal volume ventilation; Ultraprotective ventilation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Participants’ timeline. *In mechanically ventilated patients. **In women of childbearing age. ***On days 1 and 2
See this image and copyright information in PMC

References

    1. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2020;47:60-73. 10.1007/s00134-020-06294-x. - PMC - PubMed
    1. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19 - preliminary report. N Engl J Med. 2020;384:693-704. 10.1056/NEJMoa2021436. - PMC - PubMed
    1. Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O, Gandini G, Herrmann P, Mascia L, Quintel M, Slutsky AS, Gattinoni L, Ranieri VM. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2007;175(2):160–166. doi: 10.1164/rccm.200607-915OC. - DOI - PubMed
    1. Chauvelot L, Bitker L, Dhelft F, Mezidi M, Orkisz M, Davila Serrano E, Penarrubia L, Yonis H, Chabert P, Folliet L, David G, Provoost J, Lecam P, Boussel L, Richard JC. Quantitative-analysis of computed tomography in COVID-19 and non COVID-19 ARDS patients: a case-control study. J Crit Care. 2020;60:169–176. doi: 10.1016/j.jcrc.2020.08.006. - DOI - PMC - PubMed
    1. Needham DM, Yang T, Dinglas VD, Mendez-Tellez PA, Shanholtz C, Sevransky JE, Brower RG, Pronovost PJ, Colantuoni E. Timing of low tidal volume ventilation and intensive care unit mortality in acute respiratory distress syndrome. A prospective cohort study. Am J Respir Crit Care Med. 2015;191(2):177–185. doi: 10.1164/rccm.201409-1598OC. - DOI - PMC - PubMed

Publication types

Associated data